Compound with cerebral apoplexy treatment characteristic as well as preparation method and application thereof
Through the complex of yeast peptide and hydroxytyrosol, combined with lecithin or phospholipid membrane, the limitations of existing stroke treatment methods are solved, effective treatment of stroke is achieved, and the area of cerebral infarction and oxidative damage is reduced, providing A safe and economical treatment plan.
Patent Information
- Application Number
- CN202411285781.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-13
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-09-13
AI Technical Summary
The existing stroke treatment methods have limitations such as narrow treatment time window, bleeding risk and side effects, and the existing neuroprotective drugs have limited efficacy and are difficult to meet clinical needs.
Using a complex of yeast peptide and hydroxytyrosol, yeast peptides are prepared by enzymatic yeast proteins by papain and combined with lecithin or phospholipid membranes to form a complex with stroke therapeutic properties, which is used to alleviate stroke and reverse in mice. Oxidative damage during ischemia and reperfusion.
This complex significantly reduces the area of cerebral infarction in mice, reduces the content of reactive oxygen species, improves the activity of superoxide dismutase, enhances the content of antioxidant glutathione, reverses oxidative damage, and has no obvious toxic side effects, providing a safe, Effective treatment methods for stroke.
Smart Images

Figure CN118903366A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and more specifically to a compound having stroke therapeutic properties and a preparation method and application thereof. Background Art
[0002] Stroke is an acute cerebrovascular disease with high morbidity, high disability and high mortality, which has brought a heavy burden to society and families. At present, the treatment of stroke mainly relies on thrombolytic therapy, antiplatelet therapy and neuroprotective therapy, but these methods have certain limitations. For example, thrombolytic therapy is limited by the narrow treatment time window and high risk of bleeding; antiplatelet therapy may cause side effects such as bleeding and gastrointestinal discomfort; and the existing neuroprotective drugs have limited efficacy and are difficult to meet clinical needs.
[0003] In recent years, with the continuous development of biotechnology, researchers have begun to explore the use of new biomolecules such as peptides and nanozymes as potential drugs for the treatment of stroke. For example, the discipline group led by Researcher Lai Ren of the Kunming Institute of Zoology, in collaboration with Professor Ni Heyu of the University of Toronto, identified an active peptide with significant therapeutic effects from the forest leech. The peptide can specifically inhibit the activity of kallikrein and factor XII, and has shown good therapeutic effects on both transient ischemic stroke and permanent ischemic stroke, and has good biosafety and anti-thrombotic effects, and has no bleeding risk, and has significant characteristics for candidate drug development.
[0004] However, the peptide needs to be obtained from forest leeches, which is inconvenient to produce and has high cost. Therefore, it is necessary to further develop new, efficient, safe and relatively low-cost peptides that have therapeutic effects on stroke to meet clinical needs. Summary of the invention
[0005] Therefore, the technical problem to be solved by the present invention is to provide an efficient, safe and economical compound with stroke treatment properties and its preparation method and application. The compound preparation method is simple, low cost, and has good therapeutic effect and biosafety.
[0006] In order to solve the above technical problems, the present invention provides the following technical solutions:
[0007] A complex with stroke therapeutic properties, the complex contains yeast peptide and hydroxytyrosol; the yeast peptide is a yeast peptide with a molecular weight greater than or equal to 1kDa and less than 3kDa produced by papain enzymolysis of yeast protein; the pH of the papain enzymolysis of yeast protein is 6.8-7.2, the enzymolysis time is 3.8-4.2h, the enzymolysis temperature is 48-52℃, and the enzyme amount / mass ratio of papain to yeast protein in the enzymolysis system is 8800-9200U / g. Experiments have shown that the yeast peptide prepared by the method has a certain effect of alleviating mouse stroke, and the complex formed by the yeast peptide and hydroxytyrosol also shows the effect of alleviating stroke and reversing oxidative damage during ischemia-reperfusion in mouse experiments.
[0008] The above-mentioned complex with stroke therapeutic properties further contains lecithin and / or a phospholipid membrane prepared by using lecithin; the preparation method of the phospholipid membrane is to dissolve lecithin in chloroform and then evaporate the chloroform. Introducing lecithin or phospholipid membrane into the complex can promote the combination of yeast peptide and hydroxytyrosol.
[0009] The above-mentioned complex with stroke therapeutic properties, when lecithin is added to the complex: the ratio of the amounts of yeast peptide, hydroxytyrosol and lecithin is (6.5~38.9): (6.5~38.9): (0.1~0.5); when phospholipid membrane is added to the complex, the amount of phospholipid membrane is calculated according to the amount of lecithin used to prepare the phospholipid membrane: the ratio of the amounts of yeast peptide, hydroxytyrosol and phospholipid membrane is (6.5~38.9): (6.5~38.9): (0.1~0.5).
[0010] The method for preparing the above-mentioned composite having stroke therapeutic properties comprises the following steps:
[0011] (1) preparing yeast protein powder dispersion by using yeast protein powder prepared from yeast;
[0012] (2) shaking the yeast protein powder dispersion at an enzymatic reaction temperature;
[0013] (3) adding papain to the yeast protein powder dispersion to perform enzymolysis, and obtaining an enzymolysis solution after the enzymolysis is completed;
[0014] (4) heating the enzymatic hydrolysate to the protease inactivation temperature and keeping the temperature, and then cooling the enzymatic hydrolysate and adjusting the pH of the enzymatic hydrolysate;
[0015] (5) centrifuging the enzymatic hydrolysate and taking the supernatant, and sequentially ultrafiltering and freeze-drying the supernatant to obtain a yeast peptide with a molecular weight greater than or equal to 1 kDa and less than 3 kDa;
[0016] (6) dispersing the yeast peptide and hydroxytyrosol in a phosphate buffer to prepare a composite system, and stirring to obtain a yeast peptide-hydroxytyrosol complex dispersion;
[0017] (7) Purifying and freeze-drying the yeast peptide-hydroxytyrosol complex dispersion to obtain a yeast peptide-hydroxytyrosol complex, wherein the yeast peptide-hydroxytyrosol complex is the above-mentioned complex with stroke therapeutic properties.
[0018] The preparation method of the above-mentioned composite with stroke therapeutic properties comprises the following steps: in step (1), a phosphate buffer is used to prepare a yeast protein powder dispersion, wherein the pH of the phosphate buffer is equal to the pH during enzymatic hydrolysis; the content of yeast protein in the yeast protein powder is greater than or equal to 80wt%, and the concentration of yeast protein powder in the yeast protein powder dispersion is 48-50g / L.
[0019] In the preparation method of the above-mentioned complex with stroke therapeutic properties, in step (2), the oscillation time is 10 to 15 minutes; in step (4), the protease inactivation temperature is 95 to 100°C, and the insulation time is 10 to 15 minutes; after the enzymatic hydrolysate is naturally cooled, the pH of the enzymatic hydrolysate is adjusted to 7.0.
[0020] In the method for preparing the above-mentioned composite having the property of treating stroke, in step (5), when the enzymatic hydrolysate is centrifuged, the centrifugation temperature is 4 to 8°C, the speed during centrifugation is 10000 to 12000 rpm, and the centrifugation time is 10 to 20 min;
[0021] In step (6), the molar ratio of yeast peptide to hydroxytyrosol in the composite system is 1:1, and the concentration of hydroxytyrosol in the composite system is 1-6 mg / mL; after the composite system is prepared, lecithin and / or a phospholipid membrane made of lecithin is added to the composite system; the amount of the phospholipid membrane in the composite system is calculated according to the molar amount of lecithin, and the molar concentration of lecithin in the composite system is 0.1-0.5 mmol / L.
[0022] In the preparation method of the above-mentioned composite with stroke therapeutic properties, in step (6), during the stirring process, the composite system is cyclically heated; the cyclic heating method is to heat the composite system to 48-52°C at a heating rate of 3-7°C / min, keep it warm for 20-30 minutes, and then naturally cool it to room temperature until the stirring is completed; the stirring time is 20-26 hours.
[0023] The preparation method of the above-mentioned composite with stroke therapeutic properties comprises the following steps: in step (1), using phosphate buffer to prepare a yeast protein powder dispersion, the pH of the phosphate buffer is 7.0; the yeast protein content in the yeast protein powder is greater than or equal to 80wt%, and the concentration of the yeast protein powder in the yeast protein powder dispersion is 50g / L;
[0024] In step (2), the shaking time is 10 min;
[0025] In step (3), the enzymatic hydrolysis time is 4 h, the enzymatic hydrolysis temperature is 50° C., the pH during the enzymatic hydrolysis is 7, and the enzyme amount / mass ratio of papain to yeast protein in the enzymatic hydrolysis system is 9000 U / g;
[0026] In step (4), the protease inactivation temperature is 100° C. and the holding time is 10 min; after the enzymatic hydrolyzate is naturally cooled, the pH of the enzymatic hydrolyzate is adjusted to 7.0;
[0027] In step (5), when the enzymatic hydrolysate is centrifuged, the centrifugation temperature is 4°C, the speed during centrifugation is 10000 rpm, and the centrifugation time is 15 min;
[0028] In step (6), the molar ratio of yeast peptide to hydroxytyrosol in the composite system is 1:1, and the concentration of hydroxytyrosol in the composite system is 5 mg / mL; after the composite system is prepared, lecithin and / or a phospholipid membrane made of lecithin is added to the composite system; the amount of phospholipid membrane in the composite system is calculated according to the molar amount of lecithin, and the molar concentration of lecithin in the composite system is 0.1 mmol / L; during the stirring process, the composite system is cyclically heated; the cyclic heating method is to heat the composite system to 50°C at a heating rate of 5°C / min, keep warm for 30 minutes, and then naturally cool to room temperature until the stirring ends; the stirring time is 24 hours. When the yeast peptide and hydroxytyrosol are compounded at a molar ratio of 1:1, the contact and combination between the yeast peptide and hydroxytyrosol are more efficient. Circular heating can promote the full contact and combination of the yeast peptide and hydroxytyrosol, and improve the formation efficiency of the composite. Temperature control helps to improve the stability of the complex and avoid degradation or inactivation of components caused by high temperature, thereby enhancing the efficacy of the complex.
[0029] The application of the above-mentioned compound with stroke therapeutic properties is used to manufacture a drug for treating ischemic stroke.
[0030] The technical solution of the present invention achieves the following beneficial technical effects:
[0031] 1. The present invention provides a complex with stroke therapeutic properties. The complex is prepared by compounding yeast peptide and hydroxytyrosol, and exhibits obvious therapeutic properties for ischemic stroke. The results of animal experiments show that the cerebral infarction area of mice injected with the yeast peptide-hydroxytyrosol complex significantly decreased, and the neurological score also significantly decreased; the yeast peptide-hydroxytyrosol complex can reduce the content of reactive oxygen species in the brain tissue of mice, increase the activity of superoxide dismutase, increase the content of antioxidant glutathione, and reverse the oxidative damage during ischemia-reperfusion without obvious toxic side effects. The complex is expected to become a new drug for the treatment of stroke, providing a safer and more effective treatment method for clinical practice.
[0032] 2. The complex of the present invention is prepared by enzymatic hydrolysis of yeast protein with papain, which has a simple process, readily available raw materials and low production cost. Compared with some polypeptide drugs that need to be extracted from special organisms, the complex of the present invention is more economical and feasible. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 TCC staining results of the brains of sham-operated mice and MCAO mice injected with PBS buffer, yeast peptides, and yeast peptide-hydroxytyrosol complexes in Example 1 of the present invention;
[0034] Figure 2 The statistical results of cerebral infarction area of the sham-operated mice and the MCAO mice injected with PBS buffer, yeast peptide and yeast peptide-hydroxytyrosol complex in Example 1 of the present invention;
[0035] Figure 3 The neurological score results of the sham-operated mice and the MCAO mice injected with PBS buffer, yeast peptide and yeast peptide-hydroxytyrosol complex in Example 1 of the present invention;
[0036] Figure 4 The results of determination of ROS content in brain tissues of sham-operated mice and tMCAO model mice injected with PBS buffer, yeast peptide and yeast peptide-hydroxytyrosol complex in Example 2 of the present invention;
[0037] Figure 5 The SOD activity measurement results of the brain tissues of the sham-operated mice and the tMCAO model mice injected with PBS buffer, yeast peptide and yeast peptide-hydroxytyrosol complex in Example 2 of the present invention;
[0038] Figure 6 The results of determination of GSH content in brain tissues of sham-operated mice and tMCAO model mice injected with PBS buffer, yeast peptide and yeast peptide-hydroxytyrosol complex in Example 2 of the present invention;
[0039] Figure 7The MDA content determination results of the brain tissues of the sham-operated mice and the tMCAO model mice injected with PBS buffer, yeast peptide and yeast peptide-hydroxytyrosol complex in Example 2 of the present invention. DETAILED DESCRIPTION
[0040] Example 1
[0041] First, the composite is prepared. The specific preparation method is as follows:
[0042] (1) Angel AnPro80 yeast protein powder is selected, and the yeast protein powder is made from yeast. The yeast protein powder has a nominal yeast protein content of 80wt%. 50g of yeast protein powder is weighed and the yeast protein powder is prepared into a yeast protein powder dispersion. The specific method is to add 50g of yeast protein powder to 1L of phosphate buffer (PBS buffer) with a pH of 7.0, and fully shake to obtain a yeast protein powder dispersion with a yeast protein powder concentration of 50g / L.
[0043] (2) The yeast protein powder dispersion is placed in a water bath thermostat oscillator at 50°C and oscillated for 10 minutes. After this step, the temperature of the yeast protein powder dispersion will be stabilized at 50°C, ensuring that the subsequent enzymatic hydrolysis reaction is carried out under appropriate temperature conditions from the beginning, thereby improving the reaction efficiency and effect.
[0044] (3) Papain is added to the yeast protein powder dispersion, and the yeast protein is hydrolyzed by papain. 9000U of papain is added to each gram of yeast protein. According to the yeast protein content of the yeast protein powder in the present embodiment of 80wt%, the concentration of yeast protein in the yeast protein powder dispersion is 40g / L, that is, 360000U of papain is added to each liter of yeast protein powder dispersion. The enzymolysis time is 4h, and the enzymolysis temperature is 50°C. After the enzymolysis is completed, an enzymolysis solution is obtained.
[0045] (4) Heat the enzymatic solution to 100°C (passivation temperature) and keep it warm for 10 minutes to inactivate the protease. After it cools naturally to room temperature, adjust the pH to 7.0 with 1 mol / L NaOH or 1 mol / L HCl.
[0046] (5) The pH-adjusted enzymatic hydrolysate was centrifuged using a low-temperature high-speed centrifuge at a centrifugation temperature of 4°C, a rotation speed of 10,000 rpm, and a centrifugation time of 15 min. After centrifugation, the supernatant was retained, and an ultrafiltration centrifuge tube was used to ultrafilter the enzymatic hydrolysate greater than or equal to 1 kDa and less than 3 kDa from the supernatant, and the yeast peptide was obtained by freeze-drying.
[0047] (6) Calculate the amount of yeast peptide and hydroxytyrosol, and mix them according to the molar ratio of yeast peptide to hydroxytyrosol of 1:1 (calculate the molar amount of yeast peptide according to the average molecular mass of yeast peptide of 1133.29Da), add yeast peptide and hydroxytyrosol to PBS buffer to prepare a composite system. The concentration of hydroxytyrosol in the composite system is 5 mg / mL, and the concentration of yeast peptide in the composite system is 36.8 mg / mL. In some other embodiments, the concentration of hydroxytyrosol in the composite system can also be other values within the range of 1 to 6 mg / mL.
[0048] In order to make yeast peptide and hydroxytyrosol combine better, lecithin or phospholipid membrane made of lecithin is added to the complex according to the ratio of 0.1 mmol / L (it can also be prepared according to any value between 0.1 and 0.5 mmol / L of lecithin or phospholipid membrane concentration, and the amount of phospholipid membrane is calculated according to the amount of lecithin used to prepare the phospholipid membrane). The preparation method of phospholipid membrane is: dissolve lecithin in chloroform and evaporate the chloroform. The relatively hydrophilic head of lecithin can combine with the alcohol hydroxyl group in hydroxytyrosol and the hydrophilic group in yeast peptide respectively, and the tail of lecithin can combine with each other. In addition, some hydrophobic groups in yeast peptide can combine with the tail of lecithin (when phospholipids are not added, these hydrophobic groups cannot combine with hydroxytyrosol). Therefore, the addition of lecithin or phospholipid membrane can promote the mutual combination of hydroxytyrosol and yeast peptide and form a complex.
[0049] After adding lecithin, the composite system is stirred while cyclic heating is performed. Circular heating means that the composite system is first heated to 50°C at a heating rate of 5°C / min, kept warm for 30 minutes, and then naturally cooled to room temperature, and this cycle is repeated, and stirring is continued for 24 hours. After the stirring is completed, a yeast peptide-hydroxytyrosol complex dispersion is obtained.
[0050] In some other embodiments, the heating rate of the cyclic heating is in the range of 3 to 7° C. / min, the temperature after heating is in the range of 48 to 52° C., and the stirring time is in the range of 20 to 26 h.
[0051] (7) Purify the yeast peptide-hydroxytyrosol complex dispersion. Transfer the yeast peptide-hydroxytyrosol complex dispersion to a centrifuge tube equipped with an ultrafiltration membrane with a molecular weight cutoff of 1 kDa and centrifuge. The centrifugation conditions are 4°C, 10,000 rpm, and 15 minutes. After centrifugation, carefully discard the filtrate that passes through the ultrafiltration membrane and retain the filtrate above the ultrafiltration membrane. In order to further remove unbound yeast peptide and hydroxytyrosol, add an appropriate amount of ultrapure water to the top of the ultrafiltration membrane, mix thoroughly, and centrifuge again. Repeat the washing and centrifugation steps twice, each time centrifuging at 4°C and 10,000 rpm for 15 minutes.
[0052] In order to test whether the prepared yeast peptide-hydroxytyrosol complex has a therapeutic effect on ischemic cerebral infarction, an animal experiment was conducted. First, an ischemic stroke mouse model (MCAO mouse model) was constructed by surgery. The specific steps are as follows:
[0053] 1. Use sodium pentobarbital (50 mg / kg) to anesthetize C57BL / 6J mice by intraperitoneal injection to ensure that the mice are completely unconscious.
[0054] 2. Make an incision about 1 cm long in the midline of the mouse's neck. Use forceps and scissors to gently separate the skin and muscles to expose the right common carotid artery, internal carotid artery, and external carotid artery.
[0055] 3. Use hemostatic forceps to gently separate and clamp the common carotid artery, internal carotid artery and external carotid artery to prevent blood flow. Make a small incision at the end of the external carotid artery (near the branch point) (this incision is the stump of the external carotid artery), insert a 30mm long 6-0 suture through the stump of the external carotid artery into the internal carotid artery, and slowly push it forward to block the middle cerebral artery.
[0056] During the surgery, the body temperature of the mouse was maintained between 37.0 and 37.5 °C using a heating pad.
[0057] In addition, a sham operation group was set up. In the sham operation group, no suture was inserted into the artery, and the rest of the steps were the same as those for the construction of the above-mentioned ischemic stroke mouse model.
[0058] MCAO mice were randomly divided into 3 groups, 6 mice in each group. After 60 minutes of MCAO (middle cerebral artery occlusion), PBS buffer, yeast peptide dispersion (prepared with PBS buffer, concentration of 0.01M) and yeast peptide-hydroxytyrosol complex dispersion (prepared with PBS buffer, concentration of 0.01M) were injected into the tail vein of the 3 groups of MCAO mice, respectively, with an injection volume of 200 μL. At the same time, the sham operation group mice were injected with an equal volume of PBS buffer.
[0059] 1.5 hours after the injection, the sutures in the blood vessels were removed to simulate clinical interventional thrombectomy and restore blood flow in the middle cerebral artery.
[0060] The mice were evaluated by neurological scoring, and then the mice were killed and the brain tissues were taken for TCC staining. Figure 1 As shown, the white part in the figure represents the cerebral infarction area, Sham represents the sham operation group, PBS represents the MCAO mice injected with PBS buffer, yeast peptide represents the MCAO mice injected with yeast peptide dispersion, and "LP@complex" represents the MCAO mice injected with yeast peptide-hydroxytyrosol complex dispersion.
[0061] The area of cerebral infarction was measured and the proportion of infarction area was calculated. Figure 2 In the figure, Sham represents the sham operation group, PBS represents the MCAO mice injected with PBS buffer, yeast peptide represents the MCAO mice injected with yeast peptide dispersion, and "LP@complex" represents the MCAO mice injected with yeast peptide-hydroxytyrosol complex dispersion. Figure 2 It can be seen that the infarct area of mice in the PBS group (i.e., the control group) was about 40% (i.e., the infarct area accounted for 40% of the brain surface area), the infarct area of mice in the yeast peptide group was about 15%, and the infarct area of mice in the yeast peptide-hydroxytyrosol complex group was about 5%. From the experimental results, the injection of yeast peptide-hydroxytyrosol complex dispersion has a significant therapeutic effect on MCAO mice, which can reduce the cerebral infarction area of MCAO mice by about 87.5% (even compared with the use of hydroxytyrosol alone, the cerebral infarction area of mice is reduced by 58.3%).
[0062] like Figure 3 The neurological score evaluation results of each group of mice. In the figure, Sham represents the sham operation group, PBS represents MCAO mice injected with PBS buffer, yeast peptide represents MCAO mice injected with yeast peptide dispersion, and "LP@complex" represents MCAO mice injected with yeast peptide-hydroxytyrosol complex dispersion. The neurological score is to evaluate the neurological function of mice, and the scoring standard is Bederson's five-point method. According to this scoring standard, the score of mice in the PBS group was 3.2, the score of mice in the yeast peptide group was 1.5, and the score of the yeast peptide-hydroxytyrosol complex group was 1.2. Judging from the scoring results, the neurological score of MCAO mice injected with yeast peptide-hydroxytyrosol complex dispersion was significantly lower.
[0063] The above results indicate that the yeast peptide-hydroxytyrosol complex prepared in this example is a complex with therapeutic properties for stroke.
[0064] Example 2
[0065] When ischemic stroke occurs, interruption of cerebral blood flow causes local brain tissue ischemia and hypoxia, and the restoration of cerebral blood flow will further cause ischemia-reperfusion injury (CIRI). It is well known that oxidative stress is an important factor that aggravates CIRI, so inhibiting oxidative stress is particularly important for alleviating neurological damage in stroke.
[0066] Experimental animals: SPF grade C57BL / 6 male mice, 8 weeks old, weighing 20-25 g.
[0067] Experimental design:
[0068] 1. Establishment of tMCAO model in mice: After anesthesia, the head and limbs of mice were fixed and placed in a supine position. After disinfection of the neck with iodine, a 1 cm incision was made in the middle. Forceps were used to separate the right common carotid artery, external carotid artery and internal carotid artery in turn. The proximal ends of the common carotid artery and external carotid artery were ligated and the distal end of the internal carotid artery was clamped with an artery clamp. A suture was reserved at the distal end of the common carotid artery, and an inverted V-shaped notch was cut at the proximal end and the arterial bifurcation to allow the line plug to enter. The line plug was inserted into the internal carotid artery through the incision. After tightening the reserved suture without affecting the movement of the line plug, the artery clamp was opened, and the line plug was pushed to the bifurcation of the internal and external arteries and fixed. The wound was sutured and iodine was applied to prevent infection. After 2 hours of MCA occlusion, the line plug was removed by 10 mm to achieve blood reperfusion for 72 hours. The modeling process of mice in the sham operation group was consistent with that of the tMCAO group, but no line plug was inserted.
[0069] 2. Group administration: The mice were randomly divided into 4 groups, 10 in each group. The corresponding reagents were injected through the tail vein, and the injection volume was 200 μL. Experimental group 1 was injected with the yeast peptide-hydroxytyrosol complex YP@HT prepared in Example 1 (prepared with PBS buffer, concentration 0.2 mg / mL), experimental group 2 was injected with the yeast peptide YP prepared in Example 1 (concentration 0.2 mg / mL), experimental group 3 was injected with hydroxytyrosol HT (concentration 0.2 mg / mL), and the sham operation group and the control group were injected with equal volumes of PBS buffer.
[0070] Evaluation of brain tissue oxidative damage:
[0071] After 7 days of administration, the mice were anesthetized and killed by cervical dislocation. The brain tissue was then quickly removed and the olfactory bulb was removed and residual blood stains were washed away in normal saline. 0.5 g of brain tissue was taken, the surface moisture was dried with filter paper, and normal saline was added in a ratio of 1:9, and the homogenate was centrifuged to obtain the supernatant. The ROS (reactive oxygen species) content and SOD (superoxide dismutase) activity, GSH (glutathione) content and MDA (malondialdehyde) content in the brain tissue were measured according to the instructions of the kit (all produced by Beyotime Bio).
[0072] Result analysis:
[0073] like Figure 4 is the ROS detection result (the vertical axis indicates that the ROS content is the multiple of the sham operation group), Figure 5 This is the result of SOD activity test. Figure 6 is the result of GSH content detection. Figure 7 This is the MDA content test result. Figure 5 to Figure 7 The sham on the horizontal axis represents the sham operation group, PBS represents the injection of phosphate buffered saline, YP@HT represents the injection of the yeast peptide-hydroxytyrosol complex prepared in Example 1, YP represents the yeast peptide prepared in Example 1, and HT represents hydroxytyrosol.
[0074] The occurrence and development of CIRI is closely related to oxidative stress. The outbreak of reactive oxygen species (ROS) produces oxidative stress. SOD is an endogenous antioxidant enzyme that scavenges free radicals. MDA is a lipid peroxidation product caused by oxidative stress (MDA content is positively correlated with the degree of oxidative damage to cells). GSH can maintain the body's normal immune activity and has antioxidant activity. The above indicators can be used as biomarkers of the degree of oxidative damage to nerve tissue.
[0075] Depend on Figure 4 to Figure 7 It can be seen that compared with the Sham group, the PBS group had low levels of SOD and GSH and increased MDA levels, indicating that oxidative damage occurred in the mouse brain tissue; the yeast peptide-hydroxytyrosol complex can reverse the above-mentioned oxidative damage, and the effect is better than that of yeast peptide and hydroxytyrosol alone.
[0076] Comparative Example 1
[0077] In this comparative example, a yeast peptide was prepared. The difference between the yeast peptide and the yeast peptide prepared in Example 1 was that during the enzymatic hydrolysis process, alkaline protease was used instead of papain, and the pH during the enzymatic hydrolysis was adjusted to 9. The other conditions and methods were the same as those in Example 1.
[0078] Comparative Example 2
[0079] In this comparative example, a yeast peptide was prepared. The difference between the yeast peptide and the yeast peptide prepared in Example 1 was that flavor protease was used instead of papain during the enzymatic hydrolysis process. The other conditions and methods were the same as those in Example 1.
[0080] Comparative Example 3
[0081] In this comparative example, a yeast peptide was prepared. The difference between the yeast peptide and the yeast peptide prepared in Example 1 was that when the yeast protein was enzymatically hydrolyzed by papain, the enzymatic hydrolysis temperature was 60° C. and the enzymatic hydrolysis time was 8 h.
[0082] Comparative Example 4
[0083] In this comparative example, a yeast peptide was prepared. The difference between the yeast peptide and the yeast peptide prepared in Example 1 was that the enzyme amount / mass ratio of papain to yeast protein in the enzymatic hydrolysis system was 12000 U / g.
[0084] When yeast protein is enzymatically hydrolyzed to prepare yeast peptides, the type of enzyme, the amount of enzyme and the conditions during enzymatic hydrolysis will affect the fragment size of the obtained yeast peptides, and then affect the amino acid composition of the collected yeast peptides with a molecular mass greater than or equal to 1kDa and less than 3kDa, and the biological properties of yeast peptides with different amino acid compositions are also different. In order to compare the yeast peptide-hydroxytyrosol complex prepared in Example 1, Comparative Example 1 and Comparative Example 2 on reducing oxidative stress damage of CI RI neural tissue, the same method as in Example 2 was used to test the neural repair effect of the yeast peptides in Comparative Examples 1, 2, 3, and 4 respectively with hydroxytyrosol complexes in the mouse tMCAO model.
[0085] Table 1 shows the measurement results of reducing oxidative stress damage in brain tissue of tMCAO model mice after injection of various yeast peptide-hydroxytyrosol complexes.
[0086] Table 1
[0087]
[0088] From the results in the table, it can be seen that the ROS content in the mice injected with the yeast peptide-hydroxytyrosol complex prepared in Example 1 (mice in Example 1 group) is lower, the SOD activity is higher, the GSH content is higher, and the MDA content is lower, indicating that the degree of oxidative stress damage to the nervous tissue of the mice in Example 1 group is lower, and the effect of the yeast peptide-hydroxytyrosol complex prepared in Example 1 on reducing oxidative stress damage to the nervous tissue of tMCAO model mice is better than that of the yeast peptide-hydroxytyrosol complex prepared in Comparative Examples 1, 2, 3 and 4.
[0089] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the claims of this patent application.
Claims
1. A compound having stroke therapeutic properties, characterized in that: The complex contains yeast peptide and hydroxytyrosol; the yeast peptide is a yeast peptide with a molecular weight greater than or equal to 1 kDa and less than 3 kDa produced by enzymatic hydrolysis of yeast protein by papain; the pH value when the papain enzymatic hydrolyzes the yeast protein is 6.8-7.2, the enzymatic hydrolysis time is 3.8-4.2 hours, the enzymatic hydrolysis temperature is 48-52°C, and the enzyme amount / mass ratio of papain to yeast protein in the enzymatic hydrolysis system is 8800-9200 U / g.
2. The compound having stroke therapeutic properties according to claim 1, characterized in that: The complex further contains lecithin and / or a phospholipid membrane prepared by using lecithin; the preparation method of the phospholipid membrane is to dissolve lecithin in chloroform and then evaporate the chloroform.
3. The compound having stroke therapeutic properties according to claim 2, characterized in that: When lecithin is added to the complex, the molar ratio of yeast peptide, hydroxytyrosol and lecithin is (6.5-38.9): (6.5-38.9): (0.1-0.5); when phospholipid membrane is added to the complex, the amount of phospholipid membrane is calculated according to the amount of lecithin used to prepare the phospholipid membrane: the molar ratio of yeast peptide, hydroxytyrosol and phospholipid membrane is (6.5-38.9): (6.5-38.9): (0.1-0.5).
4. A method for preparing a compound having stroke therapeutic properties, characterized in that: The following steps are involved: (1) preparing yeast protein powder prepared from yeast into a yeast protein powder dispersion; (2) shaking the yeast protein powder dispersion at an enzymatic reaction temperature; (3) adding papain to the yeast protein powder dispersion to perform enzymolysis, and obtaining an enzymolysis solution after the enzymolysis is completed; (4) heating the enzymatic hydrolysate to the protease inactivation temperature and keeping the temperature, and then cooling the enzymatic hydrolysate and adjusting the pH of the enzymatic hydrolysate; (5) centrifuging the enzymatic hydrolysate and taking the supernatant, and sequentially ultrafiltering and freeze-drying the supernatant to obtain a yeast peptide with a molecular weight greater than or equal to 1 kDa and less than 3 kDa; (6) dispersing the yeast peptide and hydroxytyrosol in a phosphate buffer to prepare a composite system, and stirring to obtain a yeast peptide-hydroxytyrosol complex dispersion; (7) Purifying and freeze-drying the yeast peptide-hydroxytyrosol complex dispersion to obtain a yeast peptide-hydroxytyrosol complex, wherein the yeast peptide-hydroxytyrosol complex is the complex with stroke therapeutic properties as claimed in claim 1.
5. The method for preparing the composite having stroke therapeutic properties according to claim 4, characterized in that: In step (1), a yeast protein powder dispersion is prepared using a phosphate buffer solution, wherein the pH of the phosphate buffer solution is equal to the pH during enzymatic hydrolysis; the content of yeast protein in the yeast protein powder is greater than or equal to 80 wt %, and the concentration of the yeast protein powder in the yeast protein powder dispersion solution is 48-50 g / L.
6. The method for preparing the composite having stroke therapeutic properties according to claim 4, characterized in that: In step (2), the oscillation time is 10 to 15 minutes; in step (4), the protease inactivation temperature is 95 to 100° C., and the insulation time is 10 to 15 minutes; after the enzymatic hydrolyzate is naturally cooled, the pH of the enzymatic hydrolyzate is adjusted to 7.
0.
7. The method for preparing the composite having stroke therapeutic properties according to claim 4, characterized in that: In step (5), when the enzymatic hydrolysate is centrifuged, the centrifugation temperature is 4 to 8°C, the speed during centrifugation is 10,000 to 12,000 rpm, and the centrifugation time is 10 to 20 min; In step (6), the molar ratio of yeast peptide to hydroxytyrosol in the composite system is 1:1, and the concentration of hydroxytyrosol in the composite system is 1-6 mg / mL; after the composite system is prepared, lecithin and / or a phospholipid membrane made of lecithin is added to the composite system; the amount of the phospholipid membrane in the composite system is calculated according to the molar concentration of lecithin, and the molar concentration of lecithin in the composite system is 0.1-0.5 mmol / L.
8. The method for preparing the composite having stroke therapeutic properties according to claim 4, characterized in that: In step (6), during the stirring process, the composite system is subjected to cyclic heating; the cyclic heating method is to heat the composite system to 48-52°C at a heating rate of 3-7°C / min, keep the temperature for 20-30 minutes, and then naturally cool to room temperature until the stirring is completed; the stirring time is 20-26 hours.
9. The method for preparing the composite having stroke therapeutic properties according to claim 4, characterized in that: In step (1), a yeast protein powder dispersion is prepared using a phosphate buffer solution, wherein the pH of the phosphate buffer solution is 7.0; the yeast protein content in the yeast protein powder is greater than or equal to 80 wt %, and the concentration of the yeast protein powder in the yeast protein powder dispersion solution is 50 g / L; In step (2), the shaking time is 10 min; In step (3), the enzymatic hydrolysis time is 4 h, the enzymatic hydrolysis temperature is 50° C., the pH during the enzymatic hydrolysis is 7, and the enzyme amount / mass ratio of papain to yeast protein in the enzymatic hydrolysis system is 9000 U / g; In step (4), the protease inactivation temperature is 100° C. and the holding time is 10 min; after the enzymatic hydrolyzate is naturally cooled, the pH of the enzymatic hydrolyzate is adjusted to 7.0; In step (5), when the enzymatic hydrolysate is centrifuged, the centrifugation temperature is 4°C, the speed during centrifugation is 10000 rpm, and the centrifugation time is 15 min; In step (6), the molar ratio of yeast peptide to hydroxytyrosol in the composite system is 1:1, and the concentration of hydroxytyrosol in the composite system is 5 mg / mL; after the composite system is prepared, lecithin and / or a phospholipid membrane made by using lecithin is added to the composite system; The amount of phospholipid membrane in the composite system is calculated according to the amount of lecithin, and the amount of lecithin in the composite system is 0.1 mmol / L; during the stirring process, the composite system is cyclically heated; the cyclic heating method is to heat the composite system to 50°C at a heating rate of 5°C / min, keep warm for 30 minutes, and then naturally cool to room temperature until the stirring ends; the stirring time is 24 hours.
10. The use of the compound having stroke therapeutic properties as claimed in any one of claims 1 to 3, characterized in that: The complex is used for preparing medicine for treating ischemic stroke.
Citation Information
Patent Citations
Application of hydroxytyrosol in preparation of VD (vascular dementia) resistant drug
CN105213356A
Anti-depression preparation for nasal mucosa administration as well as preparation method and application of anti-depression preparation
CN116270429A
Establishment method of beer yeast polypeptide extraction process and beer yeast polypeptide extraction process
CN118028410A
Yeast peptide-hydroxytyrosol compound with high ROS (reactive oxygen species) capturing capacity as well as preparation method and application of yeast peptide-hydroxytyrosol compound
CN118845983A
Method for selectively inhibiting reuptake of serotonin and norepinephrine using yeast extract
US20060140974A1
